{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["47(6)"],"submitter":["Javelot H"],"pubmed_abstract":["The use of psychotropics during the COVID-19 pandemic has raised two questions, in order of importance: first, what changes should be made to pharmacological treatments prescribed to mental health patients? Secondly, are there any positive side effects of these substances against SARS-CoV-2? Our aim was to analyze usage safety of psychotropics during COVID-19; therefore, herein, we have studied: (i) the risk of symptomatic complications of COVID-19 associated with the use of these drugs, notably central nervous system activity depression, QTc interval enlargement and infectious and thromboembolic complications; (ii) the risk of mistaking the iatrogenic impact of psychotropics with COVID-19 symptoms, causing diagnostic error. Moreover, we provided a summary of the different information avai"],"journal":["L'Encephale"],"pagination":["564-588"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8410507"],"repository":["biostudies-literature"],"pubmed_title":["Psychotropics and COVID-19: An analysis of safety and prophylaxis."],"pmcid":["PMC8410507"],"pubmed_authors":["Leboyer M","Meyer G","Yrondi A","Weiner L","Javelot H","Haffen E","Dizet S","Hingray C","Langree B","Fossati P","Gaillard R","Fakra E","Llorca PM","Drapier D","Straczek C","Gitahy Falcao Faria C","Masson M","Weibel S"],"additional_accession":[]},"is_claimable":false,"name":"Psychotropics and COVID-19: An analysis of safety and prophylaxis.","description":"The use of psychotropics during the COVID-19 pandemic has raised two questions, in order of importance: first, what changes should be made to pharmacological treatments prescribed to mental health patients? Secondly, are there any positive side effects of these substances against SARS-CoV-2? Our aim was to analyze usage safety of psychotropics during COVID-19; therefore, herein, we have studied: (i) the risk of symptomatic complications of COVID-19 associated with the use of these drugs, notably central nervous system activity depression, QTc interval enlargement and infectious and thromboembolic complications; (ii) the risk of mistaking the iatrogenic impact of psychotropics with COVID-19 symptoms, causing diagnostic error. Moreover, we provided a summary of the different information avai","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-04-05T07:12:36.677Z","creation":"2022-02-11T14:12:55.93Z"},"accession":"S-EPMC8410507","cross_references":{"pubmed":["34548153"],"doi":["10.1016/j.encep.2021.08.002"]}}